Abstract
Immune thrombocytopenia or ITP is a debilitating and life-threatening disorder affecting more than 4 in every 10, 000 adults annually. Following a basic understanding of the immunopathology underlying ITP, namely that production of anti-platelet antibodies results in accelerated platelet clearance and thrombocytopenia, animal models of ITP were quickly developed. Rodent models that develop ITP spontaneously or by passive transfer of anti-platelet sera or antibodies have become instrumental in investigating the mechanisms responsible for the breakdown of tolerance in human ITP, understanding the immunopathology that underlies the progression of platelet destruction, elucidating the mechanism(s) of therapeutic amelioration of the ITP, and driving the development of new therapeutic modalities. This review aims to capture the development history and methodology of currently available ITP disease models, and review their advantages and limitations in the study of various aspects of ITP. We also review how closely the various ITP models reflect the pathobiology of human ITP and their usefulness in advancing the development of new therapeutics, which are particularly needed to address the unmet need of patients who are refractory to the currently available repertoire of interventions.
Keywords: Mouse models of immune thrombocytopenia, ITP, autoimmune disease, platelets, IVIg.
Current Pharmaceutical Design
Title:Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia
Volume: 21 Issue: 18
Author(s): Anton Neschadim and Donald R. Branch
Affiliation:
Keywords: Mouse models of immune thrombocytopenia, ITP, autoimmune disease, platelets, IVIg.
Abstract: Immune thrombocytopenia or ITP is a debilitating and life-threatening disorder affecting more than 4 in every 10, 000 adults annually. Following a basic understanding of the immunopathology underlying ITP, namely that production of anti-platelet antibodies results in accelerated platelet clearance and thrombocytopenia, animal models of ITP were quickly developed. Rodent models that develop ITP spontaneously or by passive transfer of anti-platelet sera or antibodies have become instrumental in investigating the mechanisms responsible for the breakdown of tolerance in human ITP, understanding the immunopathology that underlies the progression of platelet destruction, elucidating the mechanism(s) of therapeutic amelioration of the ITP, and driving the development of new therapeutic modalities. This review aims to capture the development history and methodology of currently available ITP disease models, and review their advantages and limitations in the study of various aspects of ITP. We also review how closely the various ITP models reflect the pathobiology of human ITP and their usefulness in advancing the development of new therapeutics, which are particularly needed to address the unmet need of patients who are refractory to the currently available repertoire of interventions.
Export Options
About this article
Cite this article as:
Neschadim Anton and Branch R. Donald, Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia, Current Pharmaceutical Design 2015; 21 (18) . https://dx.doi.org/10.2174/1381612821666150316123436
DOI https://dx.doi.org/10.2174/1381612821666150316123436 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
IL-27: Friend or Foe in the Autoimmune Diseases
Current Immunology Reviews (Discontinued) Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety Leukocyte Function-Associated Antigen-1: Structure, Function and Application Prospects
Protein & Peptide Letters Effect of Recombinant Human Thymosin-α1, an Immuno-Modulating Peptide with 28 Amino Acids, on the Activity of Cytochrome P450s
Drug Metabolism Letters Polypeptide Delivery Across The Blood-Brain Barrier
Current Drug Targets - CNS & Neurological Disorders Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes
Current Pharmacogenomics Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Recognition of Peptides by Antibodies and Investigations of Affinity Using Biosensor Technology
Combinatorial Chemistry & High Throughput Screening Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Immuno - Functionalized Silver Nanoparticles for Diagnostics, Therapeutics and Protection of Rabies Viral Infection
Current Nanomedicine PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) From Cannabis to Endocannabinoids in Multiple Sclerosis: A Paradigm of Central Nervous System Autoimmune Diseases
Current Drug Targets - CNS & Neurological Disorders Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design The New Immunosuppression: Intervention at the Dendritic Cell-T-Cell Interface
Current Drug Targets - Immune, Endocrine & Metabolic Disorders